The Company’s corporate governance report will be prepared for the first time for the financial year 2023.
Cinclus Pharma AB (publ) is a Swedish public limited liability company.
The Company applies the Swedish Corporate Governance Code (the “Code”). Any deviation from the Code will be reported in the Company’s corporate governance report, which will be prepared for the first time for the 2023 financial year. However, in the first corporate governance report, the Company is not required to explain non-compliance with such rules that have not been relevant during the period covered by the corporate governance report. Currently, the Company does not expect to report any deviations from the Code in the corporate governance report.
Once the Company has been listed on Nasdaq Stockholm, the Company will also apply the rules in Nasdaq's Nordic Main Market Rulebook for Issuers as well as Rules on remuneration to senior executives and on incentive programs (the “Remuneration Rules”). The remuneration rules apply to all Swedish companies whose shares are listed on a regulated market in Sweden and must be fully applied from the time of listing.